Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.
Chronic fatigue syndrome
Inflammation
Mitochondrial dysfunction
Myalgic encephalomyelitis
Oxidative stress
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
06
05
2019
revised:
26
08
2019
accepted:
06
09
2019
pubmed:
12
9
2019
medline:
1
7
2020
entrez:
12
9
2019
Statut:
ppublish
Résumé
Myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) is a common and disabling condition with a paucity of effective and evidence-based therapies, reflecting a major unmet need. Cognitive behavioural therapy and graded exercise are of modest benefit for only some ME/CFS patients, and many sufferers report aggravation of symptoms of fatigue with exercise. The presence of a multiplicity of pathophysiological abnormalities in at least the subgroup of people with ME/CFS diagnosed with the current international consensus "Fukuda" criteria, points to numerous potential therapeutic targets. Such abnormalities include extensive data showing that at least a subgroup has a pro-inflammatory state, increased oxidative and nitrosative stress, disruption of gut mucosal barriers and mitochondrial dysfunction together with dysregulated bioenergetics. In this paper, these pathways are summarised, and data regarding promising therapeutic options that target these pathways are highlighted; they include coenzyme Q
Identifiants
pubmed: 31509764
pii: S1043-6618(19)30801-1
doi: 10.1016/j.phrs.2019.104450
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104450Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.